ADenoViruses as novel clinical treatments.
ADVance is designed to integrate eight leading academic centres and four private companies under a single umbrella to create an opportunity to train young scientists in adenovirus (AdV) research. Research and industrial partners represent internationally leading centres of excellence in key facets of research in the basic biology of AdV and their application as vectors for clinical protocols in cancer, cardiovascular disease and vaccination. This is a wholly unique training opportunity for our research fellows. Our academic and private sector full partners represent key areas critical to improved understanding of adenovirus biology and development of key underpinning technology for translational AdV research at the highest level.